Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tool could help stop malaria spread by reading Parasite's mind

NCT ID NCT06064591

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study of 458 people in Burkina Faso aims to develop a tool that estimates how often malaria parasites switch to a form that can spread to mosquitoes. Researchers will measure certain biomarkers in blood samples from people with and without malaria symptoms. The goal is to better predict and ultimately interrupt malaria transmission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this tool could help predict and reduce malaria transmission by identifying when parasites are most likely to spread.
What could go wrong
This is an observational study, not a treatment trial. The tool is still being developed and validated, so it may not lead to immediate public health changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

458 people

The number who actually took part.

Started

Dec 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pilot: This study will be performed at the policlinic of ITM, in Antwerp, Belgium. WP1 Recruitment screenings will be organized in Nanoro village, within the catchment area of the existing health demographic surveillance system (HDSS) of Nanoro Health district (NHD), Burkina Faso. WP2 The study will include pediatric patients with uncomplicated and severe malaria (aged ≥ 1 and ≤ 12 years, male and female) visiting Chókwè Rural Hospital, Mozambique, and the peripheral health centers in Chókwè district.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: ≥ 1 year * Willing and able to provide written informed consent (or assent for minors with written informed consent by parent(s) and/or guardian(s). Pilot: -symptomatic for P. falciparum -/Travel to P. falciparum endemic area within the last month WP1: * Resident in Nanoro district * non-symptomatic individuals WP2: * Positive for P. falciparum infection via Rapid Diagnostic Tests (RDT) * Age: ≥ 1 and ≤ 12 years * Patients are included when suspected of the following conditions: I. Severe malaria by infection with P. falciparum is defined in the presence of P. falciparum asexual parasitemia, and as one or more of the following: 1. Impaired consciousness: A Blantyre coma score \< 3 (when patients are ≤ 6 years) or Glasgow coma score \< 10 (when patients are ≥ 6 years). 2. Prostration: Generalized weakness so that the person is unable to sit, stand or walk without assistance. 3. Multiple convulsions: More than two episodes within 24 hours. 4. Clinical manifestation of respiratory distress (e.g., rapid, deep and labored breathing). 5. Diagnosis through exclusion: absence of an identified alternative cause. II. Uncomplicated malaria by infection with P. falciparum is defined as a patient who presents with lethargic profile (e.g. fever) and a positive parasitological test for P. falciparum, but with no features of severe malaria. Exclusion Criteria: * Delayed developmental status or history of chronic illness * Participation in another study * Previous malaria treatment or prophylaxis in the last week * Inability or unwillingness of the parents or guardians to provide informed consent WP1: * Symptoms of malaria, as defined by presence of fever (body temperature \>37.5 °C or history of fever during the past 48 hours) with a positive RDT (RDT are performed always when there is presence of fever) * Any plans to leave the study are in the coming 10 days WP2: * Severe anemia (will be determined via clinical examination), since blood samples can hardly be withdrawn, co-morbidities. * A questionnaire will be used during the clinical assessment that addresses following exclusion criteria: x Antimalarial drug treatment or other medication during the past week x If the patient had a meal within 4 hours before admission x Patients with acute meningitis (as clinically evaluated according to the local guidelines) x Patients with developmental delay or history of chronic illness x Vaccination during the past week

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asyptomatic plasmodium infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut de Recherche en Sciences de la Santé - Clinical Research Unit of Nanoro

    Nanoro, Burkina Faso

  • Institute of Tropical Medicine Antwerp

    Antwerp, Antwerp, 2000, Belgium

  • Instituto Nacional de Saúde (INS)

    Maputo, Mozambique

More trials for these conditions

Other studies related to the condition(s) this trial covers.